Thrombotic microangiopathy (TM), manifesting clinically as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, is an uncommon complication after bone marrow transplantation (BMT). A retrospective analysis of potential risk factors for TM following allogeneic BMT was performed. Clinical data were analyzed from seven patients diagnosed with severe TM and 409 patients who underwent BMT during the same time period and who survived for at least 100 days afterwards. Six of the seven patients with TM received intensive GVHD prophylaxis consisting of cyclosporine, methotrexate and glucocorticoids, whereas only 66 of the 409 patients without TM received this regimen (P Ͻ 0.001, Fisher's exact test). This regimen was administered to patients older than 40 years, or recipients of a mismatched or unrelated allograft. Univariate analysis also revealed an increased risk of TM associated with the use of an unrelated bone marrow donor (P = 0.02), but no significant association with patient age or gender, diagnosis, amount of prior chemotherapy, transplant conditioning regimen or severity of GVHD. A multivariate exact logistic regression analysis revealed that only the type of GVHD prophylaxis had a significant impact on the risk for TM. The combined use of cyclosporine, methotrexate and glucocorticoids as GVHD prophylaxis may predispose to the development of TM following BMT. Keywords: thrombotic thrombocytopenic purpura; hemolytic uremic syndrome; bone marrow transplantation; graftversus-host disease Thrombotic microangiopathy (TM) is a pathological process characterized by occlusion of the microvasculature by hyaline thrombi resulting in microangiopathic hemolytic anemia, thrombocytopenia and end organ dysfunction. Clinically, TM manifests as hemolytic uremic syndrome (HUS) when the renal vasculature is primarily affected, or as thrombotic thrombocytopenic purpura (TTP) when there There is a well-documented association between infection with E. coli strain O157:H7 and the occurrence of HUS.
1
There is a well-documented association between infection with E. coli strain O157:H7 and the occurrence of HUS. 2, 3 Individuals infected with the human immunodeficiency virus have an increased incidence of TTP. 4 TM also occurs in relation to pregnancy; TTP tends to occur in the ante-partum period while HUS is more frequent post-partum. 1 Administration of chemotherapy, especially mitomycin C, has been associated with the development of HUS. 5 These various etiologies are thought to share the ability to induce injury to the vascular endothelium. Plasma exchange is highly effective therapy for TTP; HUS may also respond to this therapy. 3, 6 TM is an uncommon complication of allogeneic bone marrow transplantation (BMT). More than 63 cases of TM have been reported to occur in this setting. 7 The first case of TM following allogeneic BMT was observed during the earliest use of cyclosporine (CsA) prophylaxis for graftversus-host disease (GVHD). 8 Subsequently, the occurrence of TM was found to be significantly associated with the use of CsA prophylaxis and the severity of GVHD in BMT patients. 9 However, TM has also been observed in patients undergoing autologous BMT and in allogeneic BMT patients who have not received CsA, suggesting that the use of the total body irradiation (TBI) and cyclophosphamide (CY) conditioning regimen might play a critical role in the etiology of BMT-related TM. 10 We recently noted an increase in the incidence of TM in patients undergoing allogeneic BMT at our institution. As a result, we conducted a retrospective analysis of disease and treatment-related variables in order to identify factors associated with the development of this complication.
Materials and methods

Patients
Seven patients were identified as having TM due to the presence of microangiopathic hemolytic anemia and progressive thrombocytopenia without laboratory evidence of disseminated intravascular coagulation (positive fibrin degradation product or d-dimer assays). Microangiopathic hemolytic anemia was defined as the presence of schistocytes on the peripheral blood smear, anemia (hemoglobin Ͻ12 mg/dl), reticulocytosis (absolute reticulocyte count Ͼ114 000/l), and elevated serum lactate dehydrogenase (LDH Ͼ220 U/l) persisting for more than 1 week in the absence of a positive direct antiglobulin test. The control patient population included all patients who had undergone allogeneic BMT at UCLA between October 1983 and June 1996, received CsA for GVHD prophylaxis and survived at least 100 days post-BMT without developing TM. All patient data were obtained from computerized records and hospital charts with the approval of the UCLA Institutional Review Board.
Prior chemotherapy
In order to assess the potential effect of chemotherapy administered prior to conditioning and transplantation, a representative sample of 30 control patients was selected so that the proportion of diagnoses was identical to that of the control population. The distribution of the subpopulation did not differ from that of the entire control population with respect to age, gender, donor status, GVHD prophylaxis, acute GVHD severity, or conditioning regimen. The prior therapy of the control subgroup then was compared to that of the TM patients.
Conditioning regimens
A large number of different regimens were used to condition patients for BMT. In order to simplify the data analysis, conditioning regimens were grouped as follows: (1) CY/TBI included CY 60 mg/kg for 2 days with TBI, total lymphoid irradiation (TLI) or both using various doses and schedules, or CY 90 mg/kg with etoposide 60 mg/kg and TBI 1200 cGy in six fractions, or CY 60 mg/kg for 2 days with TBI 1125 cGy in five fractions and vincristine 0.2 mg/kg for 2 days; (2) cytosine arabinoside (Ara-C)/CY/TBI included Ara-C 0. 
GVHD prophylaxis and treatment
All study patients received CsA for GVHD prophylaxis. No conventions for the selection of GVHD prophylaxis were consistently followed during the study period. However, indications for the use of triple immunosuppressive therapy consisting of CsA, MTX and glucocorticoids included patients over 39 years of age, or those receiving bone marrow from an unrelated or mismatched related donor.
Administration of CsA was begun on day −1 by giving 3 mg/kg intravenously over 12 h, followed by 3 mg/kg/day for patients р35 years or 2 mg/kg/day for patients Ͼ35 years by continuous intravenous infusion. When patients were tolerating oral medications, the intravenous dose of CsA was administered orally twice daily. Doses were adjusted to maintain serum levels between 200 and 400 ng/ml. CsA was administered for 6 months to related BMT patients and 12 months to unrelated BMT patients, after which time the dose was tapered by 25 mg/day each week in the absence of active GVHD. Methotrexate (MTX) 15 mg/m 2 was given intravenously on day 1, and 10 mg/m 2 on days 3 and 6 following BMT. Either methylprednisolone (Mpred) or prednisone was administered twice daily at 0.5 mg/kg on days +3 to +42, once daily at 0.5 mg/kg on days +43 to +56 and once daily at 0.3 mg/kg on days +57 to +100, then tapered over 1 month in the absence of GVHD. Acute GVHD was diagnosed and graded according to standard clinical criteria.
11 Treatment was individualized depending on disease severity, but initially consisted of Mpred 2 mg/kg/day. Higher Mpred doses with or without antithymocyte globulin were administered depending on the initial response to therapy.
Therapeutic apheresis and response to treatments
Plasma exchange was performed using a Cobe Spectra device (Lakewood, CO, USA) to replace one plasma volume with fresh frozen plasma on a daily basis. The staphylococcal protein A column (PROSORBA column; IMRÉ Corp., Seattle, WA, USA) was used in the setting of unresponsive or progressive TM in spite of plasma exchange. One liter of plasma was processed through the PROSORBA column using a Cobe Spectra machine every other day.
Statistical analysis
Nine variables were evaluated for possible association with TM: age (age Ͼ median vs age р median, where median was 27 years), gender, diagnosis, donor type (related vs unrelated and HLA-identical vs mismatched), transplant date (10/83-12/88 vs 1/89-6/96), conditioning regimen, use of TBI, GVHD prophylaxis regimen and GVHD severity. Univariate analysis was performed using Fisher's exact test (two-tailed). Factors having univariate associations or borderline associations with TM were further investigated in a logistic model to assess the additive effects of these variables and their interactions on the occurrence of TM and to confirm the lack of association with the remaining variables. Multivariate logistic analysis was performed using exact methods (LogXact). 12 Additional analyses were performed using, as the control group, only 296 of the 409 control patients who were over the age of 16 years (median age 33). These results were similar to the analysis for the full cohort and are not included.
Results
Patients with TM following BMT
Seven patients (mean ± s.d., age, 37 ± 12 years) who underwent allogeneic BMT at UCLA between October 1983 and June 1996 were diagnosed with TM. The clinical and laboratory characteristics of the TM patients are shown in Tables 1 and 2 . TM was diagnosed between 47 and 105 a Prior to diagnosis of TM. ALL = acute lymphocytic leukemia; CML = chronic myelocytic leukemia; AML = acute myelocytic leukemia; BMT = bone marrow transplant; TBI = total body irradiation; Ara-C = cytarabine; CY = cyclophosphamide; BU = busulfan; GVHD = graft-versus-host disease; CsA = cyclosporine; MTX = methotrexate; GCs = glucocorticoids; aGVHD = acute GVHD. 
days after BMT. The majority of the patients had fevers and neurological abnormalities but it was sometimes difficult to determine whether these were due to TM, concurrent infection or liver dysfunction. Three patients had acute renal insufficiency at the time TM was diagnosed.
Clinical features associated with TM
The clinical characteristics of the TM patients were compared to those of 409 control patients (mean ± s.d. age, 26 ± 13 years) who had undergone allogeneic BMT at UCLA between October 1983 and June 1996, received CsA for GVHD prophylaxis and survived at least 100 days following BMT (Table 3 ). Univariate analysis revealed that the use of a three-drug regimen consisting of CsA, MTX and glucocorticoids for GVHD prophylaxis (six of seven patients with TM vs 66 of 409 controls; P = 0.0007, Fisher's exact test), or use of an unrelated bone marrow donor (four of seven vs 68 of 409; P = 0.019) was associated with the occurrence of TM in our patient population. Use of TBI was similar in each group (five of seven vs 294 of 409; P = 1.0). A representative subgroup of 30 control patients was compared to the TM patients to assess the association of the amount of previous chemotherapy on the risk for TM. Of the 30 control patients, 10 received no prior therapy, 10 had one to two courses of prior chemotherapy, and 10 underwent more than two courses of treatment or a previous bone marrow transplant. The numbers for the TM patients for the same categories were two, three and two, respectively. Therefore, previous treatment of the TM patients did not differ from that of the control group. Other variables including patient age or gender, diagnosis, BMT conditioning regimen, date of transplant, or GVHD severity also had no association with the development of TM (Table 3) . Exact logistic regression analysis showed that after controlling for the type of GVHD prophylaxis, no other variables had a significant association with the occurrence of TM.
Outcome of therapy for TM
CsA was discontinued in all but one patient when TM was diagnosed. There was no amelioration of the TM as a result of CsA discontinuation. All of the patients underwent therapeutic apheresis with plasma exchange; three patients also had apheresis with the use of a staphylococcal protein A column ( Table 4) . None of the patients had any evidence of hematological or clinical improvement as a result of the apheresis procedures. All of the patients died between 15 and 307 days following the diagnosis of TM. Although all of the patients had active TM at the time of death, TM was not the primary cause of death in any of the cases.
Discussion
The GVHD prophylaxis regimen of CsA, MTX and glucocorticoids was found to be associated with an increased risk of developing TM in our patient population. Because this AA = aplastic anemia; PNH = paroxysmal nocturnal hemoglobinuria; HD = Hodgkin's disease; NHL = nonHodgkin's lymphoma; TLI = total lymphoid radiation. regimen was primarily employed in patients with a high risk for developing acute GVHD it is difficult to determine whether the increased risk of TM was related to the immunosuppressive regimen or to the risk factors for which the prophylaxis was given. Age over 39, or use of bone marrow from an unrelated or mismatched related donor were the indications for the use of triple immunosuppression. Our analysis, and those of previous publications, have not identified increased age as a risk factor for TM. Univariate analysis did reveal that the use of unrelated donor bone marrow was statistically associated with the development of TM. However, the multivariate analysis failed to demon-strate an additive effect of donor status on TM risk after controlling for GVHD prophylaxis regimen. Because these variables are closely linked and our sample size is small, it may be difficult to exclude the use of an unrelated donor as an independent risk factor for developing TM. This association has not been reported previously, but the majority of papers describing BMT-related TM preceded the use of unrelated donors. In recent reports of TM following allogeneic BMT, 33-89% of patients suffering this complication received their bone marrow from an unrelated donor. [13] [14] [15] [16] The GVHD prophylaxis regimens used by each center were not described in detail, but at the Royal Hospital for Sick Children, where T cell depletion of the graft and CsA were used for GVHD prophylaxis, 89% of the patients who developed TM had undergone an unrelated transplant. 15 This suggests that recipients of an unrelated BMT may have an increased risk of developing TM compared to those receiving bone marrow from a matched sibling, independent of GVHD prophylaxis regimen.
Although TM was primarily observed in patients at high risk for acute GVHD, the severity of acute GVHD experienced by the TM patients was not significantly different from that observed in the control patients. These findings differ from those of a previous study in which BMT patients with grade II or greater acute GVHD had a significantly higher incidence of TM than those with grade 0 or 1 GVHD. 9 We also failed to identify a significant association between the use of TBI conditioning regimen and the development of TM. This suggests that radiation does not play an essential role in the causation of TM, as was previously proposed. 10 CsA has many biological effects that could contribute to the causation of TM. CsA inhibits the ability of cultured human endothelial cells to produce prostacyclin (PGI 2 ) in response to arachidonic acid, thrombin or calcium ionophores. 17, 18 Administration of CsA to rats leads to increased renal excretion of thromboxane B 2 (TxB 2 ), the stable metabolite of TxA 2 , suggesting that CsA induces increased renal synthesis of TxA 2 .
19 Impaired PGI 2 production or enhanced TxA 2 elaboration resulting from CsA administration could cause vasoconstriction and enhanced platelet aggregability. CsA also has been reported to have a direct cytotoxic effect on vascular endothelial cells in vitro. 20 Endothelial cell damage could result in the exposure of subendothelial collagen and further augment platelet aggregation. There is clinical evidence that CsA can induce vascular endothelial cell injury in vivo. Elevated serum levels of von Willebrand factor (vWF), a protein synthesized and released by the vascular endothelium, were observed in renal transplant recipients experiencing CsA nephrotoxicity. 21 Elevated serum vWF levels were also observed in allogeneic BMT patients receiving CsA, but not MTX, as GVHD prophylaxis; patients who developed TM while receiving CsA had the highest vWF levels. 22 Another vascular endothelial protein, thrombomodulin, was present at elevated levels in the plasma of patients with CsA nephrotoxicity, consistent with induction of endothelial injury by CsA. 23 In addition to its effects on endothelial cells, CsA also affects platelet function. CsA directly increases the aggregation of normal platelets in response to adenosine diphosphate (ADP), epinephrine or collagen in vitro. 24 A similar effect occurs in vivo: platelets obtained from normal individuals or renal allograft recipients treated with CsA are hyperaggregable in response to ADP or epinephrine. 24, 25 CsA-treated renal allograft patients have diminished platelet ADP and ATP pools, and have persistently elevated serum platelet factor 4 levels, suggesting that chronic platelet activation is occurring. 25 The importance of CsA in the pathogenesis of post-BMT TM is supported by reports of TM occurring in patients receiving CsA following solid organ transplantation. Patients treated with CsA after receiving a renal or hepatic allograft have developed HUS. 26, 27 Because TM developed in these patients in the absence of chemotherapy or radiation treatment, and without the development of GVHD or graft rejection, it appears that CsA administration alone may be sufficient to induce TM in some individuals. Our findings suggest that additional treatment-related variables may increase the risk of developing TM in patients receiving CsA after BMT.
Glucocorticoids (GCs) affect vascular endothelial cells in a manner that could enhance the prothrombotic effects of CsA. GCs block endothelial cell production and release of the vasodilators PGE 2 and PGI 2 in response to various stimuli. [28] [29] [30] [31] [32] [33] [34] Administration of GCs to thrombocytopenic rabbits results in a dose-dependent shortening of the bleeding time which may result from inhibition of endothelial PGI 2 production and consequent augmentation of platelet aggregation. 29 GCs also stimulate vascular endothelial cell synthesis of fibronectin matrix, which is capable of inducing platelet adhesion to the subendothelium by binding glycoprotein IIb/IIIa on platelet surface membranes. 35 The prolonged administration of both CsA and GCs may result in an increased risk of developing TM. Recently, allogeneic BMT patients receiving Mpred and CsA for GVHD prophylaxis were found to have significantly higher serum LDH levels, lower platelet counts and higher plasma von Willebrand factor antigen levels than patients receiving MTX and CsA as GVHD prophylaxis. 22 Three of 14 patients who received GCs and CsA in that series developed TM. All but one of our patients who developed TM received GCs, CsA and MTX as prophylaxis for GVHD. The relative contribution of the GCs or MTX to the risk for TM cannot be assessed because no patient who received either GCs or MTX alone with CsA developed TM. The use of GCs or MTX as single agents, even in high doses, has not been associated with an increased risk of TM. Therefore, it is likely that the increased frequency of TM in our patients derives from the combined effects of several treatment-related variables.
Plasma exchange or the use of a staphylococcal protein A column was unsuccessful in treating TM in our patients, all of whom died of their underlying diseases or transplantrelated complications. Previous experience with the use of plasma exchange or a staphylococcal protein A column for TM following allogeneic BMT resulted in mixed success. There have been at least 53 such patients reported in the literature to date. [13] [14] [15] [16] [36] [37] [38] [39] [40] [41] [42] [43] [44] Nineteen of 33 patients treated with plasma exchange alone had some clinical improvement, but only seven responding patients survived.
Responses to plasma exchange were often incomplete and almost all survivors had persistent renal insufficiency. Although early experience with a staphylococcal protein A column was negative, recent reports from the Western Pennsylvania Cancer Institute suggest that a regimen of alternating plasma exchange using cryoprecipitate-poor plasma and apheresis with a protein A column is effective in approximately half of post-BMT TM patients. 14, 16 In general, patients with allogeneic BMT-related TM often die from infection, progressive GVHD, complications of the TM or relapse of the underlying disease. Survival has been shown to correlate inversely with the severity of the TM, which can be determined by the level of serum lactate dehydrogenase and the percentage of schistocytes on the peripheral blood smear. 44 The poor response of BMT-associated TM to plasma exchange in this series may partly be due to the presence of concomitant life-threatening disorders in most of the patients or the severe nature of their TM.
Our patients had serious TM at the time that it was appreciated. Because patients may often experience protracted cytopenias following allogeneic BMT the diagnosis of TM may be delayed. Retrospectively, most patients had laboratory abnormalities suggestive of TM for days to weeks prior to the time that it was clinically evident. Given the often poor response of severe BMT-associated TM to standard therapy, early intervention may be of benefit. BMT patients receiving an aggressive immunosuppressive regimen should be monitored closely for the development of this complication so that treatment can be instituted early in the course of the disease. Alternatively, because the benefit of triple immunosuppression in patients at high risk for GVHD has not been clearly established, a prospective clinical trial should be conducted to determine the impact of this regimen on the survival of this patient population.
